ABVX France: Euronext Paris

    Abivax S.A.

    Last Updated: Oct 19, 2021 5:35 p.m. CEDT Delayed quote


    -0.25 -0.83%
    Previous Close
    Advanced Charting
    Volume: 24.67K 65 Day Avg: 20.51K
    120% vs Avg
    29.30 Day Range 31.25
    16.62 52 Week Range 39.00

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ABVX Overview


    5 Day
    • 10.20%
    1 Month
    • -6.01%
    3 Month
    • -4.81%
    • -13.66%
    1 Year
    • 56.32%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 4 Full Ratings

    Recent News

    Abivax stock surges 9% on trial results for ulcerative colitis therapy

    Abivax stock surges 7% on trial results for ulcerative colitis therapy

    No Headlines Available

    Abivax S.A.

    Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development comprise of vaccine for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.


    Name Chg % Market Cap
    Fermentalg S.A. 0.90% €91.78M
    Transgene S.A. 1.05% €231.74M
    Cellectis S.A. 4.61% €414.28M
    Competitor Data Provided ByCapital Cube Logo